Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease

Velma T. E. Aho, Madelyn C. Houser, Pedro A. B. Pereira, Jianjun Chang, Knut Rudi, Lars Paulin, Vicki Hertzberg, Petri Auvinen, View ORCID ProfileMalú G. Tansey, Filip Scheperjans
doi: https://doi.org/10.1101/2020.06.15.20131011
Velma T. E. Aho
1DNA Sequencing and Genomics Laboratory, Institute of Biotechnology, University of Helsinki, Viikinkaari 5D, 00790, Helsinki, Finland
2Department of Neurology, Helsinki University Hospital, and Department of Neurological Sciences (Neurology), University of Helsinki, Haartmaninkatu 4, 00290 Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Madelyn C. Houser
3Nell Hodgson Woodruff School of Nursing, 1520 Clifton Rd., Emory University, Atlanta, GA 30322, USA
4Department of Physiology, 615 Michael St., Emory University School of Medicine, Atlanta, GA 30322, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pedro A. B. Pereira
1DNA Sequencing and Genomics Laboratory, Institute of Biotechnology, University of Helsinki, Viikinkaari 5D, 00790, Helsinki, Finland
2Department of Neurology, Helsinki University Hospital, and Department of Neurological Sciences (Neurology), University of Helsinki, Haartmaninkatu 4, 00290 Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jianjun Chang
4Department of Physiology, 615 Michael St., Emory University School of Medicine, Atlanta, GA 30322, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Knut Rudi
5Faculty of Chemistry, Biotechnology and Food Science (KBM), Norwegian University of Life Sciences, 1433 Ås, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lars Paulin
1DNA Sequencing and Genomics Laboratory, Institute of Biotechnology, University of Helsinki, Viikinkaari 5D, 00790, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vicki Hertzberg
3Nell Hodgson Woodruff School of Nursing, 1520 Clifton Rd., Emory University, Atlanta, GA 30322, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Petri Auvinen
1DNA Sequencing and Genomics Laboratory, Institute of Biotechnology, University of Helsinki, Viikinkaari 5D, 00790, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Malú G. Tansey
4Department of Physiology, 615 Michael St., Emory University School of Medicine, Atlanta, GA 30322, USA
6Department of Neuroscience and Neurology, Center for Translational Research in Neurodegenerative Disease, 1149 Newell Dr., University of Florida, Gainesville, FL 32611, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Malú G. Tansey
  • For correspondence: mgtansey@UFL.edu filip.scheperjans@hus.fi
Filip Scheperjans
2Department of Neurology, Helsinki University Hospital, and Department of Neurological Sciences (Neurology), University of Helsinki, Haartmaninkatu 4, 00290 Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mgtansey@UFL.edu filip.scheperjans@hus.fi
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Previous studies have reported that gut microbiota, permeability, short-chain fatty acids (SCFAs), and inflammation are altered in Parkinson’s disease (PD), but how these factors are linked and contribute to disease processes and symptoms remains uncertain.

Objectives This study sought to compare and identify associations among these factors in PD patients and controls to elucidate their interrelations and links to clinical manifestations of PD.

Methods Stool and plasma samples and clinical data were collected from 55 PD patients and 56 controls. Levels of stool SCFAs and stool and plasma inflammatory and permeability markers were compared between patients and controls and related to one another and to the gut microbiota.

Results Calprotectin was increased and SCFAs decreased in stool in PD in a sex-dependent manner. Inflammatory markers in plasma and stool were neither intercorrelated nor strongly associated with SCFA levels. Age at PD onset was positively correlated with SCFAs and negatively correlated with CXCL8 and IL-1β in stool. Fecal zonulin correlated positively with fecal NGAL and negatively with PD motor and non-motor symptoms. Microbiota diversity and composition were linked to levels of stool SCFAs, inflammation, and zonulin. These relationships differed somewhat between patients and controls and by sex.

Conclusions Intestinal inflammatory responses and reductions in fecal SCFAs occur in PD, are related to the microbiota and to disease onset, and are not reflected in plasma inflammatory profiles. Some of these relationships are PD- and sex-dependent. Alterations in microbiota-host interactions and links between intestinal inflammation and reduced SCFA levels and earlier PD onset warrant further investigation.

Competing Interest Statement

VTEA, PABP, LP, PA, and FS have patents FI127671B & US10139408B2 issued and patents US16/186,663 & EP3149205 pending that are assigned to NeuroInnovation Oy and licensed to NeuroBiome Ltd. FS is founder and CEO of NeuroInnovation Oy and NeuroBiome Ltd., is a member of the scientific advisory board and has received consulting fees and stock options from Axial Biotherapeutics. MGT is an advisor to INmune Bio, Longevity Biotech, Prevail Therapeutics, and Weston Garfield Foundation. MGT has patents issued (US Pat. Nos. 7144987B1 and 7244823B2) and pending (US20150239951, WO2019067789, 62/901698, see efiling Ack37193677, 62/905747, see efilingAck37274773) for co-invention of DN-TNFs.

Funding Statement

This study was funded by the Michael J. Fox Foundation for Parkinsons Research, the Academy of Finland (295724, 310835), the Finnish Medical Foundation, and the Hospital District of Helsinki and Uusimaa (UAK1014004, UAK1014005, TYH2018224.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the ethics committee of the Hospital District of Helsinki and Uusimaa. All participants gave informed consent.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Financial Disclosure/Conflict of Interest: This study was funded by the Michael J. Fox Foundation for Parkinson’s Research, the Academy of Finland (295724, 310835), the Finnish Medical Foundation, and the Hospital District of Helsinki and Uusimaa (UAK1014004, UAK1014005, TYH2018224.

  • VTEA, PABP, LP, PA, and FS have patents FI127671B & US10139408B2 issued and patents US16/186,663 & EP3149205 pending that are assigned to NeuroInnovation Oy and licensed to NeuroBiome Ltd.

  • FS is founder and CEO of NeuroInnovation Oy and NeuroBiome Ltd., is a member of the scientific advisory board and has received consulting fees and stock options from Axial Biotherapeutics.

  • MGT is an advisor to INmune Bio, Longevity Biotech, Prevail Therapeutics, and Weston Garfield Foundation. MGT has patents issued (US Pat. Nos. 7144987B1 and 7244823B2) and pending (US20150239951, WO2019067789, 62/901698, see efiling Ack37193677, 62/905747, see efilingAck37274773) for co-invention of DN-TNFs.

Data Availability

All statistical analyses were performed in R37 with packages including phyloseq,38 vegan,39 and DESeq240 for microbial data comparisons. The complete R code is included as a supplementary file (Supplementary R Markdown), and full analysis details are available in Supplementary materials.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted June 19, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease
Velma T. E. Aho, Madelyn C. Houser, Pedro A. B. Pereira, Jianjun Chang, Knut Rudi, Lars Paulin, Vicki Hertzberg, Petri Auvinen, Malú G. Tansey, Filip Scheperjans
medRxiv 2020.06.15.20131011; doi: https://doi.org/10.1101/2020.06.15.20131011
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease
Velma T. E. Aho, Madelyn C. Houser, Pedro A. B. Pereira, Jianjun Chang, Knut Rudi, Lars Paulin, Vicki Hertzberg, Petri Auvinen, Malú G. Tansey, Filip Scheperjans
medRxiv 2020.06.15.20131011; doi: https://doi.org/10.1101/2020.06.15.20131011

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Neurology
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (142)
  • Anesthesia (44)
  • Cardiovascular Medicine (408)
  • Dentistry and Oral Medicine (67)
  • Dermatology (47)
  • Emergency Medicine (141)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4816)
  • Forensic Medicine (3)
  • Gastroenterology (177)
  • Genetic and Genomic Medicine (671)
  • Geriatric Medicine (70)
  • Health Economics (187)
  • Health Informatics (621)
  • Health Policy (314)
  • Health Systems and Quality Improvement (200)
  • Hematology (85)
  • HIV/AIDS (155)
  • Infectious Diseases (except HIV/AIDS) (5282)
  • Intensive Care and Critical Care Medicine (326)
  • Medical Education (91)
  • Medical Ethics (24)
  • Nephrology (73)
  • Neurology (677)
  • Nursing (41)
  • Nutrition (112)
  • Obstetrics and Gynecology (124)
  • Occupational and Environmental Health (203)
  • Oncology (438)
  • Ophthalmology (138)
  • Orthopedics (36)
  • Otolaryngology (88)
  • Pain Medicine (35)
  • Palliative Medicine (15)
  • Pathology (128)
  • Pediatrics (193)
  • Pharmacology and Therapeutics (129)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (769)
  • Public and Global Health (1799)
  • Radiology and Imaging (321)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (61)
  • Surgery (100)
  • Toxicology (23)
  • Transplantation (28)
  • Urology (37)